Table 2.

Baseline characteristics of responders and non-responders to Switzerland hemagglutinin antigen.

	NoR n = 20	R n = 15	p-value*
CHARACTERISTICS AT TIME OF TRANSPLANTATION
Recipient
Age at transplantation (years)	53 ± 13	51 ± 16	0.74
Origin of renal disease, n (%)			0.80
Glomerulonephritis	1 (5)	3 (20)
Diabetes mellitus	3 (15)	2 (13)
Vascular	6 (30)	4 (27)
Genetic	4 (20)	3 (20)
Uropathy	1 (5)	1 (7)
Undetermined	5 (25)	2 (13)
Duration of dialysis (months)	21 ± 20	31 ± 43	0.83
DONOR
Donor age (years)	50 ± 14	48 ± 17	0.71
Donor sex, men, n (%)	14 (70)	11 (73)	1.0
Deceased donor, n (%)	17 (85)	14 (93)	0.69
Extended criteria donor, n (%)	6 (30)	7 (47)	0.48
TRANSPLANTATION
Number of HLA-A, B, C, DR, DQ mismatches	6.1 ± 1.5	5.2 ± 1.9	0.17
Combined kidney-pancreas transplantation, n (%)	2 (10)	1 (7)	1.00
Cold ischemia time (min)	677 ± 414	806 ± 490	0.40
Delayed graft function, n (%)	0 (0)	3 (21)	0.06
CHARACTERISTICS AT TIME OF VACCINATION
Time elapsed since transplantation (months)	23 ± 19	24 ± 15	0.77
IMMUNOSUPPRESSION
Induction therapy
Thymoglobuline, n (%)	17 (85)	9 (60)	0.12
Maintenance regimen
Tacrolimus, n (%)	19 (95)	10 (67)	0.06
Ciclosporin, n (%)	1 (5)	5 (33)
mTOR-Inhibitors, n (%)	2 (10)	1 (7)	1.00
Mycophenolate, n (%)	18 (90)	14 (93)	1.00
Azathioprin, n (%)	1 (5)	0
Prednisone, n (%)	12 (60)	12 (80)	0.28
GRAFT FUNCTION
eGFR (ml/min/m2)	59 ± 22	61 ± 23	0.78
Proteinuria**, n (%)	3 (15)	3 (20)	1.00

^*Unpaired t-test was used for comparison of continuous variables and Fisher's exact test was used for comparison of proportions.

^**Proteinuria is defined as >0.5 g/24 h or >40 mg/mmol creatinine in spot-urine.

mTOR, mammalian target of rapamycin; eGFR, estimated glomerular filtration rate.